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Abstract: The amino acid β-N-methylamino-L-alanine (L-BMAA) has been 
associated with the amyotrophic lateral sclerosis/parkinsonism-dementia 
complex in three distinct western Pacific populations. The putative neurotoxin 
is produced by cyanobacteria, which live symbiotically in the roots of cycad 
trees. L-BMAA was thought to be a threat only to those few populations whose 
diet and medicines rely heavily on cycad seeds. However, the recent discovery 
that cyanobacteria from diverse terrestrial, freshwater, and saltwater ecosys-
tems around the world produce the toxin requires a reassessment of whether it 
poses a larger health threat. Therefore, it is proposed that monitoring L-BMAA 
levels in cyanobacteria-contaminated water supplies might be prudent. 
Keywords:  β-N-methylamino-L-alanine; neurodegenerative diseases; neuro-
toxicity; environmental toxin. 
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1. INTRODUCTION 
It has been well established that cyanobacterial and other environmental 
toxins cause and/or promote the development of a vast variety of diseases and 
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disturbances in both animals and men.1–3 Environmentally available excitatory 
amino acids are a good example. When ingested, or otherwise introduced into an 
organism, they can induce numerous disturbances of the nervous system. One of 
the excitatory amino acids that has received a lot of attention lately is β-N-me-
thylamino-alanine (BMAA). 
β-N-Methylamino-alanine is a highly reactive, low molecular weight amino 
acid (MW 118 g mol–1) with unusual chemistry, originating as a result of its 2-
amino groups being only partially ionized under physiological conditions.4 It was 
first isolated by Vega and Bell5 in 1967 as a result of an effort to isolate a 
causative agent of the amyotrophic lateral sclerosis/Parkinsonism-dementia com-
plex of the Western Pacific (ALS/PDC). 
The Western Pacific amyotrophic lateral sclerosis/Parkinsonism–dementia 
complex has been reported in three genetically and ethnically distinct population 
groups residing in Guam (Chamorros of the Marianas Islands), Japan (Japanese 
residents of the Kii Peninsula, Honshu Island) and New Guinea (indigenous 
people of South West Papua or Irian Jaya, Indonesia). This disease presents a 
spectrum of neurological disorders with unusually high incidence, characterized 
by features of ALS, Parkinsonism, dementia, or a combination of these.6 
BMAA is proposed to contribute to ALS/PDC based on its presence in Cy-
cad seeds which have been singled out as the strongest epidemiological link to 
the disease, and constitute a dietary or medicinal item in all the afflicted popula-
tions. It is noteworthy that BMAA passes the blood–brain barrier,7,8 and its bio-
availability in primates, when orally administered, is 80 %.9 
Although the role of BMAA in human neurodegenerative disease is still de-
bated,10,11 a series of investigations both in vitro and in vivo has unequivocally 
established that the amino acid is indeed a neurotoxin. 
2. THE BMAA NEUROTOXICITY 
The first report describing BMAA-induced neurotoxicity was made the same 
year the amino acid was first isolated. Bell and colleagues presented the results at 
the 5th Cycad Conference in 1967. They administered natural and synthetic BMAA 
intraperitoneally to chicks. The symptoms produced by both natural and synthetic 
BMAA were general unsteadiness in standing, followed by loss of ability to ex-
tend the legs and stand erect. The head was often bend down, the feet were no 
longer held straight, and the chicks would often fall over and were unable to get 
up. They showed head circling movements and head retraction. Higher doses of 
BMAA increased the proportion of chicks affected, decreased the period between 
injection and the appearance of toxic symptoms and lengthened the period of 
intoxication.12 
The landmark paper showing the neurotoxic effects of BMAA in primates 
was published in 1987 by Spencer and colleagues.13 One-year-old male cyno-
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molgus monkeys received by gavage varying doses of L-BMAA (100–315 mg 
kg–1 daily for up to 12 weeks). They were clinically and neuropathologically 
examined, and also evaluated neurophysiologically. Neurological deficits ap-
peared insidiously after 2–12 weeks and signs of motor neuron dysfunction de-
veloped symmetrically or asymmetrically. Clinical and electrophysiological signs 
of motor deficit preceded the appearance of physical alterations in the corres-
ponding areas of the CNS. The regional susceptibility to L-BMAA showed a gra-
dation from motor cortex to spinal cord to substantia nigra (from most affected to 
least affected). In this study, Spencer et al.13 showed clinical, neurophysiological 
and neuropathological evidence that L-BMAA induces a primate motor system 
disorder with involvement of the upper and lower motor neurons and the extra-
pyramidal system. 
Numerous investigations that followed confirmed the neurotoxic properties 
of BMAA. It was shown that in rats, BMAA causes acute motoric and behavioral 
deficits,14–18 signs of cerebellar dysfunction,14,15 and hyperexcitability with body 
shakes, convulsions and epileptiform activity on EEG.19,20 Neuropathologically, 
BMAA has caused postsynaptic vacuolization and neurodegeneration of corti-
cal,21 spinal cord,22 and hippocampal23 neurons in mice, as well as neurodegene-
ration of cerebellar,14,24 and monoaminergic16,25 neurons in rats. 
In a recent investigation, Karlsson et al.26 studied the transfer of BMAA to 
fetal and neonatal brains and the effects of BMAA on the development of be-
havioral characteristics in rodents. The study revealed transplacental transfer of 
(3)H-BMAA and a significant uptake in fetal mouse brain. The radioactivity was 
specifically located in the hippocampus, striatum, brainstem, spinal cord and ce-
rebellum of 10-day-old mice. BMAA treatment on postnatal days 9–10 induced 
acute alterations in the behavior of neonatal rats, such as impaired locomotive 
ability and hyperactivity. The observed behavioral changes also suggested pos-
sible cognitive impairment.26 The same group reports that rats treated with BMAA 
during the neonatal period displayed acute but transient motoric disturbances, 
long-term learning impairments and failed to show habituation at a juvenile age.27 
Santucci and coworkers28 provided further evidence supporting a direct cau-
sal link between L-BMAA and neuronal damage. The authors studied the effect 
of L-BMAA on cell viability in vivo by measuring the electrophysiological acti-
vity of mouse retinal neurons by electroretinography recordings. Intra-ocular in-
jections of L-BMAA selectively reduced the amplitude of the b-wave, without af-
fecting either the a-wave amplitude or the a- and b-latencies. Death of retinal 
cells was evidenced by histology on retina sections, caspase 3 activation, incur-
poration of propidium iodide and production of reactive oxygen species. Co-in-
jection of the specific NMDA antagonist, MK-801, significantly protected the re-
tinal neurons from L-BMAA/NMDA-induced apoptosis.28 
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Finally, BMAA exhibited toxicity in various aquatic animal species, inc-
luding zebra fish (Danio rerio), brine shrimp (Artemia salina) and the protozoan 
Nassula sorex, with the toxic responses presented as clonus convulsions and ab-
normal spinal axis formation (D. rerio), loss of phototaxis (A. salina) and mor-
talities (all species),29 while dietary intake of BMAA reduced the lifespan as well 
as the neurological functions of Drosophila melanogaster flies.30 
Of particular relevance to human health, in two independent laboratories 
where blinded brain tissue samples were tested, both found BMAA in patients 
who had died of neurodegenerative disease but not in patients who died of causes 
unrelated to neurodegeneration.  
Murch et al.31 showed that BMAA occurs in the brains of Guamanians dying 
of ALS/PDC (average concentration 627 µg g–1, 5 mM) but not in control brains. 
Moreover, they reported that BMAA was present in the brain tissues of North 
American patients who had died of Alzheimer’s disease (average concentration 
95 µg g–1, 0.8 mM).31 Although Snyder et al.,32 using a different HPLC method 
and other assay techniques, were unable to reproduce the findings of Murch et 
al.,31 Pablo and colleagues,33 using the original techniques of Murch and co-
workers,31 recently confirmed the presence of protein-bound BMAA in postmor-
tem brain specimens taken from neuropathologically confirmed cases of 13 ALS, 
12 Alzheimer’s disease (AD), and 8 Huntington’s disease North American pa-
tients. The authors reported the presence of BMAA in concentrations exceeding 
100 µg g–1 in patients who had died with sporadic AD and ALS but not in the 
brains of non-neurological controls or Huntington’s disease patients.33 
3. MECHANISMS OF BMAA NEUROTOXICITY 
The greatest initial insight into the mechanisms of BMAA neurotoxicity was 
provided by electrophysiological studies. In a breakthrough paper, Weiss and 
Choi reported that the neurotoxic potential of BMAA is greatly enhanced in the 
presence of physiological concentrations of bicarbonate ions.34 They went on to 
show that, in presence of bicarbonate, BMAA acts on NMDA ionotropic gluta-
mate receptors causing marked depolarization of the membrane potential.35 Allen 
and coworkers later confirmed these findings, but reported that the effect can be 
blocked by antagonists of non-NMDA ionotropic glutamate receptors.36  
Nedeljkov et al. investigated the effects of L-BMAA on Retzius nerve cells 
of isolated ganglia of the leech Haemopis sanguisuga and showed that the pre-
sence of bicarbonate ions produces a 4-fold increase in BMAA-induced depola-
rization of the membrane potential.37 Lopicic and colleagues, using the same 
model, reported that application of both 1 mmol L–1 L-BMAA in Ringer solution 
containing 20 mmol L–1 bicarbonate caused a significant 74 % decrease in the 
input resistance of directly polarized membrane and that the non-NMDA receptor 
antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) at a concentration of 
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100 μmol L–1 decreased the effect of L-BMAA on membrane potential by 57 %. 
The authors also presented evidence for a rise in the intracellular Na+ concentra-
tion (Na+)c and decrease in the intracellular K+ concentration (K+)c during BMAA 
induced depolarizations. The application of 2 mmol L–1 L-BMAA in bicarbonate 
Ringer for 4 min led to an average increase of (Na+)c by 30.13±13.21 mmol L–1, 
indicating a rapid influx of sodium into the cell, while the same concentration of 
L-BMAA produced a decrease of (K+)c by 15.76±0.43 mmol L–1, indicating a 
rapid efflux of K+ from the cell.38 
BMAA was also shown to produce a rise in the intracellular Ca2+ concentra-
tion,39–41 and induce oxidative stress. Rao et al.40 examined the effects of BMAA 
on reactive oxygen species (ROS) production in motor neurons from dissociated 
mouse spinal cord cultures using the oxidant-sensitive fluorophore, hydroethidine 
(HEt). The cells were loaded with HEt and imaged before and after 30 min ex-
posure to BMAA (1–3 mM). The motor neurons showed significant increases in 
HEt oxidation several minutes after addition of BMAA and the BMAA-induced 
ROS generation was dose dependent.40 Lobner and coworkers41 investigated the 
mechanisms of BMAA toxicity on mixed cortical cell cultures containing neu-
rons and astrocytes, prepared from fetal (15–16-day gestation) mice. Cellular oxi-
dative stress was measured with the fluorescent dye dichlorofluorescein (DCF). 
Exposure to 3 mM BMAA for 3 h caused a significant increase in oxidative 
stress which was blocked by the free radical scavenger trolox.41 
The presented evidence that BMAA acts via ionotropic glutamate receptors, 
increases the intracellular Na+ and Ca2+ concentrations and induces oxidative 
stress all indicate that the amino acid might cause neurodegeneration through the 
mechanism of excitotoxicity. 
Recently, Liu et al.42 proposed that the mechanism of neurotoxicity of 
BMAA may be three-fold, involving not only direct action on the ionotropic glu-
tamate receptors, but also activation of the metabotropic glutamate receptor 5 
(mGluR5) and induction of oxidative stress unrelated to excitotoxicity. They found 
that BMAA inhibits the cystine/glutamate antiporter (system Xc−) mediated 
cystine uptake, which in turn leads to glutathione depletion and increased oxide-
tive stress. BMAA also appears to drive glutamate release via the system Xc− 
and this glutamate induces toxicity through activation of the mGluR5 receptor.42 
Finally, the latest results by Nunn and Ponnusamy4 provide evidence that se-
veral biochemical mechanisms are also involved in the neurotoxicity of BMAA. 
The authors showed that BMAA changes the distribution of taurine, glycine and 
serine between rat brain slices and their incubation medium. The glutamate/glu-
tamine cycle between neurons and glia was also compromised as a result of 
BMAA administration. In model experiments, BMAA reacted non-enzymatically 
with pyridoxal-50-phosphate, releasing methylamine, and methylamine was also 
formed in rat liver and kidney homogenates when incubated with BMAA. The 
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formation and release of methylamine is significant since chronic administration 
of methylamine to rats caused oxidative stress.4 
4. BMAA AND THE ENVIRONMENT 
The renewed interest in L-BMAA as an environmental neurotoxin stemmed 
from a series of papers by Cox et al.4 They first established that the source of L- 
-BMAA in Cycas palms are cyanobacteria of the genus Nostoc living as endo-
symbionts in the corraloid roots of the palm.43 Axenic cultures of Nostoc isolated 
from corraloid roots of C. micronesica were found to produce 0.3 µg g–1 BMAA, 
while roots with flourishing cyanobacterial infections had 37 µg g–1 BMAA. 
Uninfected roots contained no BMAA.43 Furthermore, Cox and coworkers pre-
sented evidence for biomagnification of BMAA through the Guamanian ecosys-
tem; from cyanobacteria (0.3 µg g–1) to Cycad seeds (up to 1161 µg g–1), to bats 
P. mariannus mariannus (3556 µg g–1), which are consumed as a delicacy in the 
diet of the people affected by ALS/PDC in Guam.43 
However, the chemical nature of BMAA would make the molecule seem a 
poor candidate for bioaccumulation within an ecosystem since, unlike other bio-
magnified compounds, BMAA is not lipophilic and thus its accumulation in fatty 
tissues would seem unlikely. This issue was resolved by Murch and colleagues.31 
The group reported that BMAA occurs not only as a free amino acid, but can also 
be released from a bound form by acid hydrolysis. After first removing free ami-
no acids from tissue samples of various trophic levels in Guam, Murch and co-
workers hydrolyzed the remaining fraction and found BMAA concentrations to 
increase 10- to 240-fold. The authors comment that this protein-bound form of 
BMAA may function as an endogenous neurotoxic reservoir, accumulating and 
being transported between trophic levels and subsequently being released during 
digestion and protein metabolism.31  
Finally, Cox et al. tested 11 Nostoc strains isolated from symbioses with 
lower and higher plants, and 30 laboratory strains of free-living cyanobacteria, 
covering all major taxonomic groups and found 8 out of 11 Nostoc strains, and 
29 out of the 30 laboratory strains contained BMAA.44 
The ubiquity of cyanobacteria in terrestrial, freshwater, brackish and marine 
environments, combined with the process of biomagnification, opened up an inte-
resting possibility for widespread exposure to BMAA in concentrations sufficient 
for neurotoxicity. This started a worldwide search for the presence of BMAA in 
the environment. 
Several methods have been reported to detect BMAA in cyanobacterial, 
plant and animal tissue samples, including high performance liquid chromategra-
phy (HPLC), gas chromatography–mass spectrometry (GC–MS), liquid chroma-
tography–heated electrospray ionization–mass spectrometry/mass spectrometry 
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(LC–ESI–MS/MS) and a method for underivatized BMAA using an amino acid 
analyzer. 
Using three different high performance liquid chromatography (HPLC) tech-
niques and two different liquid chromatography/mass spectrometry (LC/MS) 
techniques, Banack and coworkers demonstrated that the marine cyanobacterial 
species represented by Nostoc  CCMED-001 produce β-N-methylamino-L-ala-
nine. The concentration of BMAA in the specimens ranged from 7 to 25µg g–1.45 
Metclaf et al. analyzed 12 environmental samples, including blooms, scum 
and mats from waterbodies throughout the United Kingdom, collected over a 14- 
-year period.46 The waterbodies from which the samples were collected consisted 
of 11 inland freshwaters and one coastal brackish water. All of the waterbodies 
are of high, and often multiple usages – seven are abstracted for drinking water 
treatment, five are used as recreational waters, four as fisheries and one for live-
stock watering. BMAA was found to be present in all the examined samples in 
concentrations ranging from 8 to 287 µg g–1. The authors also reported the oc-
currence of BMAA in waterbodies which are used for drinking water after treat-
ment. Whether the processes of drinking water treatment remove or destroy BMAA 
requires investigation. 
The use of cyanobacteria has also been reported in the Peruvian highlands.47 
The colonies of Nostoc commune (locally called llullucha) are harvested by indi-
genous peoples from high altitude vernal pools and lakes throughout the Peruvian 
Andes, and sold on the local markets. The colonies are used for food and medi-
cine. As food, the colonies are preferred fresh, but can also be sun-dried to pre-
serve them for the dry season. Nostoc commune is also used as a famine food, 
particularly when potatoes are scarce. Furthermore, llullucha is locally believed 
to be rich in calcium and is given to children as a milk substitute, and represents 
an ingredient of a local stew called picante. 
Medicinally, Nostoc is used in the Peruvian highlands to treat fevers and in-
flammation; it is drunk after maceration. It is also applied topically by wrapping 
mashed Nostoc in a cloth around the waist overnight to treat stomach, liver, and 
kidney pain or taken internally after boiling for the same ailments. Large colonies 
are also macerated and applied topically to assist in the final stages of a difficult 
labor and delivery. 
Johnson and coworkers tested 21 samples of Nostoc commune from seven 
local markets for the presence of BMAA and found it present in all the samples 
in concentrations ranging from 2.04 to 21.51 µg g–1.47 
Esterhuizen and Downing investigated for the presence of BMAA in cyano-
bacterial cultures representing taxonomic diversity and geographic distribution in 
southern Africa.48 The cyanobacteria were collected from various freshwater im-
poundments that are used for agricultural and recreational activities, as well as 
from raw water sources for potable water production. All strains, except one, 
2011 Copyright (CC) SCS
_____________________________________________________________________________________________________________________________________________ Available online at www.shd.org.rs/JSCS/486 LOPIČIĆ et al. 
were reproducibly positive for BMAA, although several cultures were below the 
limit for quantification. Where BMAA could be quantified, it was found to be 
present in concentrations of 0.05–2755.6 µg g–1. No correlation between the 
BMAA concentrations was observed within or between taxonomic groups or 
geographic locations. However, considerable difference in the BMAA content 
was found between extracts from different culture phases for the same strain, 
indicating that a number of factors, such as growth conditions, culture age and 
history, or nutritional or environmental stress, could influence the BMAA content 
in cyanobacteria.49 
Li et al. have analyzed axenic cultures of Microcystis aeruginosa and Nostoc 
sp. at various growth stages, isolated from Chinese freshwaters, for BMAA. 
BMAA was detected in the Nostoc sp., but at very low concentrations (<0.07 
pmol on column),49 and BMAA was also detected in blue-green algae used for 
food supplements, freshwater fish and bottled water.50 
Cox and coworkers report that cyanobacterial crusts and mats that are wide-
spread in the deserts of Qatar contain BMAA.51 These cyanobacterial crusts, which 
help bind the desert sands, are dormant throughout most of the year, but during 
brief spring rains actively photosynthesize. When disturbed by vehicular traffic 
or other activities, the dried crusts and mats can produce considerable amounts of 
dust, leading to significant exposure to BMAA and other cyanotoxins through in-
halation. Since veterans of the 1990–1991 Gulf War younger than 45 years of age 
were reported to have an increased incidence of ALS compared to personnel who 
were not deployed, the authors went on to conclude that inhalation of BMAA, 
and other aerosolized cyanotoxins, may constitute a significant risk factor for the 
development of ALS and other neurodegenerative diseases.51 
A cluster of ALS patients with incidence of the disease 10- to 25-times high-
er than expected, recorded in Enfield, New Hampshire, USA, was also linked to 
chronic exposure to BMAA and other cyanotoxins, since the town encompasses 
Lake Mascoma, which has a history of cyanobacteria algal blooms.52 The authors 
suggested that possible routes of toxin exposure include inhalation of aerosolized 
toxins, consumption of fish, or ingestion of lake water. 
BMAA-containing cyanobacteria were also found in drinking water sources 
and small pools within the Gobi Desert. Since such pools of water are crucial 
resources for wildlife inhabiting the area, the authors suggested assessment of 
cyanotoxin effects on organisms living in the Gobi Desert and other desert envi-
ronments.53 
Faassen and coworkers analyzed mixed species scum material from Dutch 
urban waters that suffer from cyanobacterial blooms. Free BMAA was detected 
at nine of the 21 sampled locations with a maximum concentration of 42 μg g–1. 
Although the BMAA concentrations were relatively low, the authors concluded 
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that co-occurrence with other cyanobacterial neurotoxins might pose a serious 
health risk.54 
Avian vacuolar myelinopathy (AVM) is a neurological disease that produces 
uncoordinated behavior in affected birds. Feeding and sentinel trials, field sur-
veys and genetic studies implicated the plant species Hydrilla verticillata (Hyd-
rocharitaceae) and an associated epiphytic cyanobacterial species (order Stigone-
matales) as a causal link to AVM. Furthermore, Stigonematales were shown to 
produce BMAA. It was suggested that if biomagnification of BMAA occurs in 
these ecosystems, as was observed in the Guam ecosystem, then the consumption 
of fish and waterfowl from AVM-confirmed reservoirs could represent a signi-
ficant human health risk.55 
5. CONCLUSIONS 
β-N-Methylamino-alanine is a neurotoxic amino acid produced by wide-
spread cyanobacteria. A possible link between this amino acid and neurodegene-
rative diseases makes it a potential risk for animal and human health. Until more 
is known about the role of BMAA in progressive neurodegenerative illnesses, it 
is suggest that monitoring for the presence of BMAA in the environment would 
be prudent. 
NOMENCLATURE 
AD Alzheimer’s  disease 
ALS  Amyotrophic lateral sclerosis 
ALS/PDC  Amyotrophic lateral sclerosis/Parkinsonism–dementia complex of the Wes-
tern Pacific 
AVM  Avian vacuolar myelinopathy 
BMAA  β-N-Methylamino-alanine 
CNQX 6-Cyano-7-nitroquinoxaline-2,3-dione 
DCF Dichlorofluorescein 
GC–MS  Gas chromatography–mass spectrometry 
HEt Hydroethidine 
HPLC  High performance liquid chromatography 
(K
+)c Intracellular  K
+ concentration 
LC/MS Liquid  chromatography/mass  spectrometry 
LC–ESI–MS/MS Liquid chromatography–heated electrospray ionization–mass spectromet-
ry/mass spectrometry 
(Na
+)c Intracellular  Na
+ concentration 
NMDA  N-Methyl-D-aspartate 
ROS  Reactive oxygen species 
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ИЗВОД 
ЕКСЦИТАТОРНА АМИНО КСЕЛИНА β-N-МЕТИЛАМИНО-L-АЛАНИН 
ЈЕ ПОТЕНЦИЈАЛНИ НЕУРОТОКСИН 
СРЂАН ЛОПИЧИЋ
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Аминокиселина β-L-метиламино-L-аланин (L-BMAA) повезана је са комплексом амио-
трофичнe латералнe склерозe/паркинсонизам–деменције који се јавља у три одвојене етнич-
ке  групе  Западног  Пацифика.  Овај  потенцијални  неуротоксин  производе  цијанобактерије 
које живе у симбиози са кореном палми из рода Cycas. Првобитно је владало мишљење да 
L-BMAA представља ризик само за наведене западнопацифичке популације које у исхрани и 
лечењу користе велике количине семена палме Cycas. Новија истраживања, међутим, пока-
зују да цијанобактерије присутне у разнородним екосистемима у земљишту, сланим и слат-
ким водама широм света такође производе ову аминокиселину. Имајући у виду потенци-
јални ризик који L-BMAA представља за здравље људи, било би важно пратити ниво ове 
аминокиселине у водама у којима су присутне цијанобактерије. 
(Примљено 29. јула, ревидирано 4. октобра 2010) 
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